









市場行情
/
股票
/
nasdaq-rgen
/

Repligen Corp

RGEN

160.660USD

+3.270+2.08%

交易中（美東）報價延遲15分鐘

9.04B總市值

5758.42本益比TTM



Repligen Corp

160.660

+3.270+2.08%

概覽公司財務分析

概覽

公司

財務

分析

關於 Repligen Corp 公司

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

Repligen Corp簡介



公司代碼RGEN

公司名稱Repligen Corp

上市日期Apr 29, 1986

CEOLoeillot (Olivier)

員工數量1778

證券類型Ordinary Share

年結日Apr 29

公司地址Building 1, Suite 100

城市WALTHAM

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02453

電話17814499560

網址https://www.repligen.com/

公司代碼RGEN

上市日期Apr 29, 1986

CEOLoeillot (Olivier)

Repligen Corp公司高管



名稱

名稱/職務

職務

持股

持股變動

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

6.02K

-53.90%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

Dr. Konstantin Konstantinov, Ph.D.

Independent Director

Mr. Jason K. Garland

Chief Financial Officer

Mr. Tony John Hunt

Executive Chairman of the Board

Dr. Martin D. Madaus, Ph.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

6.02K

-53.90%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

North America

89.36M

49.00%

Europe

69.30M

38.00%

APAC/Other

23.71M

13.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月8日週一

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

8.94%

BlackRock Institutional Trust Company, N.A.

8.24%

T. Rowe Price Associates, Inc.

6.14%

Roy T. Eddleman UEO

5.88%

United Capital Financial Advisors, LLC

4.90%

其他

65.91%

持股股東

佔比

The Vanguard Group, Inc.

8.94%

BlackRock Institutional Trust Company, N.A.

8.24%

T. Rowe Price Associates, Inc.

6.14%

Roy T. Eddleman UEO

5.88%

United Capital Financial Advisors, LLC

4.90%

其他

65.91%

股東類型

持股股東

佔比

Investment Advisor

59.79%

Investment Advisor/Hedge Fund

29.04%

Hedge Fund

15.73%

Individual Investor

6.33%

Research Firm

2.20%

Pension Fund

2.00%

Bank and Trust

0.71%

Sovereign Wealth Fund

0.60%

Family Office

0.50%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

1027

55.23M

98.12%

-6.26M

2025Q2

1028

61.98M

110.32%

-3.21M

2025Q1

1054

62.91M

111.98%

-2.72M

2024Q4

1054

61.13M

109.11%

-3.76M

2024Q3

1046

60.75M

108.48%

-6.10M

2024Q2

1039

61.28M

109.67%

-2.73M

2024Q1

1036

60.56M

108.45%

-5.41M

2023Q4

1062

62.13M

111.29%

-2.30M

2023Q3

1063

61.47M

110.27%

+2.91M

2023Q2

1050

59.01M

105.99%

+1.34M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

5.07M

-2.87K

-0.06%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.71M

8.37%

-180.36K

-3.69%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.43M

6.1%

-3.13M

-47.69%

Aug 31, 2025

Roy T. Eddleman UEO

3.31M

5.89%

-67.50K

-2.00%

Dec 31, 2024

Fidelity Management & Research Company LLC

1.36M

2.43%

+842.96K

+161.67%

Jun 30, 2025

State Street Investment Management (US)

1.62M

2.88%

-66.31K

-3.93%

Jun 30, 2025

Citadel Advisors LLC

1.06M

1.89%

-266.68K

-20.06%

Jun 30, 2025

Point72 Asset Management, L.P.

1.91M

3.4%

+796.75K

+71.36%

Jun 30, 2025

Holocene Advisors, LP

936.81K

1.67%

-23.17K

-2.41%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

First Trust NYSE Arca Biotechnology Index Fund

3.45%

Alger Mid Cap 40 ETF

3.1%

Congress SMid Growth ETF

2.46%

iShares Health Innovation Active ETF

2.28%

VanEck Biotech ETF

1.34%

Franklin Genomic Advancements ETF

1.23%

Pacer US Export Leaders ETF

1.18%

Alger 35 ETF

1.15%

WisdomTree BioRevolution Fund

1.06%

iShares Biotechnology ETF

0.7%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.45%

Alger Mid Cap 40 ETF

佔比3.1%

Congress SMid Growth ETF

佔比2.46%

iShares Health Innovation Active ETF

佔比2.28%

VanEck Biotech ETF

佔比1.34%

Franklin Genomic Advancements ETF

佔比1.23%

Pacer US Export Leaders ETF

佔比1.18%

Alger 35 ETF

佔比1.15%

WisdomTree BioRevolution Fund

佔比1.06%

iShares Biotechnology ETF

佔比0.7%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Repligen Corp的前五大股東是誰？



Repligen Corp的前五大股東如下：
The Vanguard Group, Inc.
持有股份：5.07M
佔總股份比例：9.00%。
BlackRock Institutional Trust Company, N.A.
持有股份：4.71M
佔總股份比例：8.37%。
T. Rowe Price Associates, Inc.
持有股份：3.43M
佔總股份比例：6.10%。
Roy T. Eddleman UEO
持有股份：3.31M
佔總股份比例：5.89%。
Fidelity Management & Research Company LLC
持有股份：1.36M
佔總股份比例：2.43%。